Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity

  • Varela Vázquez, Adrián
  • Guitián-Caamaño, Amanda
  • Carpintero-Fernández, Paula
  • Carneiro Figueira, Alexander
  • Álvarez, Vanesa
  • Varela-Eirín, Marta
  • Calleja-Chuclá, Teresa
  • Bravo López, Susana Belén
  • Vidal, Anxo
  • Sendón Lago, Juan José
  • Rodríguez-Candela-Mateos, Marina
  • Caeiro, José Ramón
  • Sanz-Moreno, Victoria
  • Aasen, Trond
  • González Blanco, Miguel
  • Sabio, Guadalupe
  • Quindós-Varela, María
  • Rivas, Carmen
  • Santamaría, David
  • Fernández-Lozano, Carlos
  • Fonseca, Eduardo
  • Huertas, Pablo
  • Sánchez-Laorden, Berta
  • Alabert, Constance
  • Mayán, María D.
[Abstract]: BRAF and MEK inhibitors (BRAF/MEKi) have radically changed the treatment landscape of advanced BRAF mutation-positive tumours. However, limited efficacy and emergence of drug resistance are major barriers for successful treatments. Here, by using relevant preclinical models, we find that Connexin43 (Cx43), a protein that plays a role in cell-to-cell communication, enhances the effectiveness of BRAF/MEKi by recruiting DNA repair complexes to lamin-associated domains and promoting persistent DNA damage and cellular senescence. The nuclear compartmentalization promoted by Cx43 contributes to genome instability and synthetic lethality caused by excessive DNA damage, which could provide a therapeutic approach for these tumours to overcome drug resistance. Based on these findings, we designed a drug combination using small extracellular vesicles (sEVs) to deliver the full-Cx43 in combination with the BRAF/MEKi. This study reveals Cx43 as a regulator of DNA repair and BRAF/MEKi response, highlighting the therapeutic potential that this approach could eventually have in the clinic to overcome the limitations of current therapies and improve treatment outcomes for patients with advanced BRAF mutant tumours., This work was supported in part through funding from a grant from Ministry of Science, Innovation and Universities (MICIU/AEI/10.13039/501100011033): PID2022−137027OB-I00 ERDF/EU and a grant from the Joint Transnational Call for Proposals for ‘European Innovative Research & Technological Development Projects in Nanomedicine’ EURONANOMED III (AC21_2/00026) (to M.D.M.); a grant from Xunta de Galicia (IN607B2020/12) (to M.D.M.); a grant from HORIZON-MSCA-2023-SE-01 (101183034) and FET-OPEN-Future and Emerging Technologies (to M.D.M.) and from EU HORIZON-CSA 101079489. TWINFLAG (to M.D.M.). A.V.-V., P.C.-F. and M.V.-E. were funded with post-doctoral fellowship (IN606B 2022/002; INB606B 2017/014 and IN606C 2021/006; IN606B-2019/004) from Xunta de Galicia. A.G.-C. was funded with a predoctoral fellowship (FIS20/00310) from ISCIII. A.C.-F. was funded with a predoctoral fellowship (IN606A 2022/038) from Xunta de Galicia. T.A. acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund (ERDF). V.S.M. was supported by the Institute of Cancer Research; Cancer Research UK (CRUK) C33043/A24478; Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre; Barts Charity; Worldwide Cancer Research 22-0329 and UKRI grant reference EP/X033392., Xunta de Galicia; IN607B2020/12, Xunta de Galicia; IN606B 2022/002, Xunta de Galicia; INB606B 2017/014, Xunta de Galicia; IN606C 2021/006, Xunta de Galicia; IN606B-2019/004, Xunta de Galicia; IN606A 2022/038, United Kingdom. Cancer Research UK (CRUK); C33043/A24478
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Endocytic trafficking of connexins in cancer pathogenesis

  • Totland, Max Zachrisson
  • Omori, Yasufumi
  • Sørensen, Vigdis
  • Kryeziu, Kushtrim
  • Brech, Andreas
  • Aasen, Trond
Cancer; Connexin; Ubiquitin, Càncer; Connexina; Ubiquitina, Cáncer; Conexina; Ubiquitina, Gap junctions are specialized regions of the plasma membrane containing clusters of channels that provide for the diffusion of ions and small molecules between adjacent cells. A fundamental role of gap junctions is to coordinate the functions of cells in tissues. Cancer pathogenesis is usually associated with loss of intercellular communication mediated by gap junctions, which may affect tumor growth and the response to radio- and chemotherapy. Gap junction channels consist of integral membrane proteins termed connexins. In addition to their canonical roles in cell-cell communication, connexins modulate a range of signal transduction pathways via interactions with proteins such as β-catenin, c-Src, and PTEN. Consequently, connexins can regulate cellular processes such as cell growth, migration, and differentiation through both channel-dependent and independent mechanisms. Gap junctions are dynamic plasma membrane entities, and by modulating the rate at which connexins undergo endocytosis and sorting to lysosomes for degradation, cells can rapidly adjust the level of gap junctions in response to alterations in the intracellular or extracellular milieu. Current experimental evidence indicates that aberrant trafficking of connexins in the endocytic system is intrinsically involved in mediating the loss of gap junctions during carcinogenesis. This review highlights the role played by the endocytic system in controlling connexin degradation, and consequently gap junction levels, and discusses how dysregulation of these processes contributes to the loss of gap junctions during cancer development. We also discuss the therapeutic implications of aberrant endocytic trafficking of connexins in cancer cells., E. Leithe acknowledges funding from the South-Eastern Norway Regional Health Authority (grant number 2016013) and the Kristian Gerhard Jebsen Foundation. T. Aasen acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund (ERDF).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Internal translation of truncated protein isoforms throughout the connexin gene family

  • Muñoz Guijarro, Maria José
  • Cabrera-Andrade, Alejandro
  • Gutierrez Aguirregabiria, Ane
  • Gönenc, Ipek Ilgin
  • Ramon y Cajal, Santiago
  • Aasen, Trond
Isoformas proteicas truncadas; Conexina, Isoformes de proteïnes truncades; Connexina, Truncated protein isoforms; Connexin, Trond Aasen acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Internal translation of truncated protein isoforms throughout the connexin gene family

  • Muñoz Guijarro, Maria José
  • Cabrera-Andrade, Alejandro
  • Gutierrez Aguirregabiria, Ane
  • Gönenc, Ipek Ilgin
  • Ramon y Cajal, Santiago
  • Aasen, Trond
Isoformas proteicas truncadas; Conexina, Isoformes de proteïnes truncades; Connexina, Truncated protein isoforms; Connexin, Trond Aasen acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Endocytic trafficking of connexins in cancer pathogenesis

  • Totland, Max Zachrisson
  • Omori, Yasufumi
  • Sørensen, Vigdis
  • Kryeziu, Kushtrim
  • Brech, Andreas
  • Aasen, Trond
Cancer; Connexin; Ubiquitin, Càncer; Connexina; Ubiquitina, Cáncer; Conexina; Ubiquitina, Gap junctions are specialized regions of the plasma membrane containing clusters of channels that provide for the diffusion of ions and small molecules between adjacent cells. A fundamental role of gap junctions is to coordinate the functions of cells in tissues. Cancer pathogenesis is usually associated with loss of intercellular communication mediated by gap junctions, which may affect tumor growth and the response to radio- and chemotherapy. Gap junction channels consist of integral membrane proteins termed connexins. In addition to their canonical roles in cell-cell communication, connexins modulate a range of signal transduction pathways via interactions with proteins such as β-catenin, c-Src, and PTEN. Consequently, connexins can regulate cellular processes such as cell growth, migration, and differentiation through both channel-dependent and independent mechanisms. Gap junctions are dynamic plasma membrane entities, and by modulating the rate at which connexins undergo endocytosis and sorting to lysosomes for degradation, cells can rapidly adjust the level of gap junctions in response to alterations in the intracellular or extracellular milieu. Current experimental evidence indicates that aberrant trafficking of connexins in the endocytic system is intrinsically involved in mediating the loss of gap junctions during carcinogenesis. This review highlights the role played by the endocytic system in controlling connexin degradation, and consequently gap junction levels, and discusses how dysregulation of these processes contributes to the loss of gap junctions during cancer development. We also discuss the therapeutic implications of aberrant endocytic trafficking of connexins in cancer cells., E. Leithe acknowledges funding from the South-Eastern Norway Regional Health Authority (grant number 2016013) and the Kristian Gerhard Jebsen Foundation. T. Aasen acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund (ERDF).